Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review von van de Meeberg, Maartje M., Schultheiss, Johannes P.D., Oldenburg, Bas, Fidder, Herma H., Huitema, Alwin D.R.

Volltext

Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease von Prins, Femke M., Hidding, Iwan J., Klaassen, Marjolein A.Y., Collij, Valerie, Schultheiss, Johannes P.D., Uniken Venema, Werna T.C., Bangma, Amber, Aardema, Jurne B., Jansen, Bernadien H., Mares, Wout G.N., Witteman, Ben J.M., Festen, Eleonora A.M., Dijkstra, Gerard, Visschedijk, Marijn C., Fidder, Herma H., Vich Vila, Arnau, Oldenburg, Bas, Gacesa, Ranko, Weersma, Rinse K.

Volltext

Reply von Mahmoud, Remi, Schultheiss, Johannes P.D., Fidder, Herma H., Oldenburg, Bas

Volltext

Letter: loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease—authors' reply von Mahmoud, Remi, Schultheiss, Johannes P. D., Fidder, Herma H., Oldenburg, Bas

Volltext

Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease von Schultheiss, Johannes P. D., Mahmoud, Remi, Louwers, Jonas M., Kaaij, Michiel T., Hellemondt, Boris P., Boeckel, Petra G., Mahmmod, Nofel, Jharap, Bindia, Fidder, Herma H., Oldenburg, Bas

Volltext

Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases – the longer the less? Authors' reply von Schultheiss, Johannes P. D., Mahmoud, Remi, Fidder, Herma H., Oldenburg, Bas

Volltext

Adherence to Adalimumab Was Not Improved by a Reminder-Based Intervention with an Electronic Needle Container von Schultheiss, Johannes P.D, Altena, Sandra, Clevers, Max R, Baas, Dominique, Jharap, Bindia, Fidder, Herma H

Volltext

Adherence to Adalimumab Was Not Improved by a Reminder-Based Intervention with an Electronic Needle Container von Schultheiss, Johannes P. D., Altena, Sandra, Clevers, Max R., Baas, Dominique, Jharap, Bindia, Fidder, Herma H.

Volltext

Earlier discontinuation of TNF‐α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects von Schultheiss, Johannes P.D., Brand, Eelco C., Lamers, Evert, Berg, Willemijn C.M., Schaik, Fiona D.M., Oldenburg, Bas, Fidder, Herma H.

Volltext

Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease von Mahmmod, Shaden, Schultheiss, Johannes P D, van Bodegraven, Ad A, Dijkstra, Gerard, Gilissen, Lennard P L, Hoentjen, Frank, Lutgens, Maurice W M D, Mahmmod, Nofel, van der Meulen–de Jong, Andrea E, Smits, Lisa J T, Tan, Adriaan C I T L, Oldenburg, Bas, Fidder, Herma H

Volltext